UTv Videos

The findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.

Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.

Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.

Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.

Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.

Khurshid R. Ghani, MBChB, MS, FRCS, discusses how results from the SOUL trial may shape clinical decision-making regarding stent placement.

“Our findings support that that we do not drop the label of cancer from grade group 1 nomenclature," says Jim C. Hu, MD, MPH.

A significant challenge lies in differentiating prostate cancer symptoms from common age-related issues.

Murilo De Almeida Luz, MD, discusses data on PSA and ALP changes in patients receiving enzalutamide plus radium-223 vs enzalutamide alone.

MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54.

A primary concern was establishing trust in the connectivity to ensure no loss in visualization or connection.

"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD.

One key approach is to increase the representation of women on editorial boards of journals and as reviewers.

Karyn S. Eilber, MD,'s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA

The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.

Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone.

"My goal [for] a lot of the advocacy that I do is that one day [patients] don't have to do our jobs for us," says Maria Uloko, MD.

“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” says Dean Elterman, MD, MSc.

Jad Chahoud, MD, MPH, MHA, discusses the mechanism of action for zanzalintinib and walks through key design elements of the STELLAR-002 trial.

“I think the big take-home message is now we've got multiple, multiple drugs showing that we can do significantly better than ADT alone," says Fred Saad, MD, FRCS.

Data showed a link between counties with higher rectal spacer use and a lower prevalence of ED at 4 to 5 years.

EV+P demonstrated superior efficacy to chemotherapy across all specified subgroups assessed.

“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD.

The approval of darolutamide in mCSPC was supported by data from the phase 3 ARANOTE trial.

“Widespread adoption of the BCG plus mitomycin regimen would actually help to resolve that BCG shortage," says Professor Dickon Hayne.

The investigators assessed EFS data from the CREST trial based on subgroups stratified by disease stage.

At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.